| Dr Thomas Frank Priolo, MD | |
|
1610 Route 88 Fl 3, Brick, NJ 08724-3018 | |
| (732) 295-6543 | |
| (732) 295-6204 |
| Full Name | Dr Thomas Frank Priolo |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1610 Route 88 Fl 3, Brick, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063918522 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 25MA11480300 (New Jersey) | Primary |
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.
BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.
George Washington University researcher Mary Ann Stepp, Ph.D., received a $2.8 million, five-year R01 grant from the National Institutes of Health to continue her 27 years of research on corneal wound healing.
Tyrosinaemia type 1 is a rare, hereditary metabolic disease that, if left untreated, can already lead to serious liver and kidney damage in infancy.
Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.
› Verified 9 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Complex Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154379626 PECOS PAC ID: 0446272298 Enrollment ID: O20060109000000 |
News Archive
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.
BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.
George Washington University researcher Mary Ann Stepp, Ph.D., received a $2.8 million, five-year R01 grant from the National Institutes of Health to continue her 27 years of research on corneal wound healing.
Tyrosinaemia type 1 is a rare, hereditary metabolic disease that, if left untreated, can already lead to serious liver and kidney damage in infancy.
Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Frank Priolo, MD 3600 Route 66 Fl 3, Neptune, NJ 07753-2645 Ph: (732) 807-0877 | Dr Thomas Frank Priolo, MD 1610 Route 88 Fl 3, Brick, NJ 08724-3018 Ph: (732) 295-6543 |
News Archive
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.
BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.
George Washington University researcher Mary Ann Stepp, Ph.D., received a $2.8 million, five-year R01 grant from the National Institutes of Health to continue her 27 years of research on corneal wound healing.
Tyrosinaemia type 1 is a rare, hereditary metabolic disease that, if left untreated, can already lead to serious liver and kidney damage in infancy.
Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.
› Verified 9 days ago
Olga Ryabinsky, PMHNP Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 940 Cedar Bridge Ave, Brick, NJ 08723 Phone: 855-436-7792 | |
Dr. Carol Ann Dobrzynski, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2890 Yorktowne Blvd, Brick, NJ 08723 Phone: 732-920-7580 Fax: 732-920-7581 | |
Dr. Mary Celeste Rorro, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 970 Route 70, Brick, NJ 08724 Phone: 732-836-6003 | |
Dr. Kristen Clark, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 985 Cedar Bridge Ave, Brick, NJ 08723 Phone: 732-477-5600 | |
Syed Khurram Raza, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1610 Rte 88, 3rd Fl, Brick, NJ 08724 Phone: 732-295-6543 | |
Dr. Raymond Baum I, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 445 Brick Blvd, Suite 206, Brick, NJ 08723 Phone: 732-903-7186 Fax: 732-903-7187 |